Last reviewed · How we verify
LIS1
At a glance
| Generic name | LIS1 |
|---|---|
| Sponsor | Xenothera SAS |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Polyspecific Antibodies in Lymphoproliferative T-cell Disorders (PHASE1, PHASE2)
- First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LIS1 CI brief — competitive landscape report
- LIS1 updates RSS · CI watch RSS
- Xenothera SAS portfolio CI